Bangkok Dusit Medical

Bangkok Dusit Medical Services Public Company Limited

BDMS

Bloomberg BDMS TB Reuters BDMS.BK



2Q24: In line with estimates

BDMS reported a 2Q24 net profit of Bt3.3bn, up 9% YoY but down 18% QoQ, in-line with INVX and market estimates as lower tax expense offset weaker EBITDA margin. Behind the YoY earnings improvement was higher revenue while the QoQ drop was due to seasonality. We expect better earnings in 2H24. Despite a 7% share price increase over the past month, valuation is undemanding at 27x 2024PE or below -2SD of its historical average. We rate it Outperform and BDMS is our top pick in the Healthcare Service sector.

2Q24: In line with estimates. BDMS reported a 2Q24 net profit of Bt3.3bn, up 9% YoY but down 18% QoQ, in line with INVX and market estimates as lower tax expense offset weaker EBITDA margin. Higher revenue led the YoY growth while the QoQ drop was due to seasonality.

Highlights:

- 2Q24 revenue was in line at Bt24.7bn, up 7% YoY but down 3% QoQ. By nationality, international patient services (27% of revenue) grew more strongly at 11% YoY (but fell 13% QoQ), driven by patients from Qatar, UAE and the US. Thai patient services (73% of revenue) grew 5% YoY (and grew 1% QoQ). By location, revenue from hospitals outside Bangkok grew 9% YoY, beating Bangkok's 5% YoY, to take 45% of total hospital revenue.
- EBITDA margin was weaker than expected at 22.3% in 1Q24, down from 22.8% in 2Q23 and 25.3% in 1Q24. We believe the YoY drop is due to lower bed utilization rate, which decreased from 65% in 2Q23 to 63% in 2Q24, attributed to a less widespread epidemic compared to the previous year.
- Tax expense was Bt756mn, a decrease of 7% YoY and 27% QoQ, giving an effective tax rate of 18% (down from 20% in 2Q23 and 1Q24), due to BOI tax privileges for its investment in digital transformation and energy-saving projects, which will last for three years.

Stronger earnings in 2H24. 1H24 results accounted for 46% of our full-year forecast but we expect stronger operations and earnings in 2H24 and thus maintain our forecast of 2024 core earnings growth of 13% YoY to Bt16bn. In 3Q24, we expect core earnings to grow YoY on higher revenue; July's revenue grew in the double digits YoY, and increase QoQ on seasonality. Our end-2024 DCF TP is Bt36/share (WACC at 7.1% and LT growth at 3%).

Risks. We are keeping an eye on the global economic slowdown and geopolitical risk that may cause clients to delay elective medical care and make it inconvenient for international patients to come to Thailand for treatment. However, we see this risk as diluted by BDMS' large revenue base from Thai patients and its diversified portfolio of international patient services. We see ESG risk as patient safety (S): BDMS has adopted a variety of quality assurance systems to provide continuous patient care.

Forecasts and valuation

Year to 31 Dec	Unit	2022	2023	2024F	2025F	2026F
Revenue	(Btmn)	88,535	97,077	104,408	111,556	117,453
EBITDA	(Btmn)	23,021	24,957	27,381	29,402	31,197
Core profit	(Btmn)	12,606	14,375	16,182	17,481	18,747
Reported profit	(Btmn)	12,606	14,375	16,182	17,481	18,747
Core EPS	(Bt)	0.79	0.90	1.02	1.10	1.18
DPS	(Bt)	0.60	0.70	0.79	0.85	0.91
P/E, core	(x)	35.0	30.7	27.3	25.2	23.5
EPS growth, core	(%)	63.0	14.0	12.6	8.0	7.2
P/BV, core	(x)	4.9	4.6	4.5	4.3	4.1
ROE	(%)	13.9	14.9	16.1	16.7	17.2
Dividend yield	(%)	2.2	2.5	2.8	3.1	3.3
EV/EBITDA	(x)	19.7	18.1	16.4	15.3	14.4
EBITDA growth	(%)	30.6	8.4	9.7	7.4	6.1

Source: InnovestX Research

See the end of this report for disclaimer

Tactical: OUTPERFORM

(3-month)

Stock data Last close (Aug 13) (Bt) 27.75 Target price (Bt) 36.00 Mkt cap (Btbn) 441.00 Mkt cap (US\$mn) 12,604 Beta L 2.74 Mkt cap (%) SET Sector % SET 5.56 Shares issued (mn) 15,892 Par value (Bt) 0.10 12-m high / low (Bt) 30 / 25 Avg. daily 6m (US\$mn) 29.60 Foreign limit / actual (%) 30/26 Free float (%) 66.7 Dividend policy (%) ≥ 50

Share performance			
(%)	1M	3M	12M
Absolute	6.7	(5.9)	(3.5)
Relative to SET	9.5	(0.2)	14.2

Source: SET, InnovestX Research

2023 Sustainability/ ESG Score	
SET ESG Ratings	AA

ESG Bloomberg Rank in the sector

1/23
1/23
1/23
1/23

ESG comment

BDMS has the highest ESG score in the sector and it is clear on its focus on sustainability with committed targets for environment, social, and governance criteria

Source: Bloomberg Finance L.P.

Analyst

Raweenuch Piyakriengkai Fundamental Investment Analyst on Securities (66-2) 949-1002 raweenuch.piyakriengkai@scb.co.th

Our view on ESG

BDMS is clear on its focus on sustainability with committed targets for environment, social, and governance criteria through material process and procedure, setting out a strategy and guidelines for all stakeholders and reviewing risks covering current and future healthcare business.

ESG Disclosure Score

Bloomberg ESG Score	g ESG Score 60.12 (2023)		CG Rating	g DJSI	SETESG	SET ESG Ratings			
Rank in Sector	tor 1/23		5	Yes	Yes	AA			
		Source: Th	Source: Thai Institute of Directors (IOD), SET						

Environmental Issue (E)

- BDMS intends to accomplish net zero emissions in 2050. It has adopted circular economy principles on energy and resource management. In addition, it plans to improve energy efficiency and ensure the least impact by business activities on the environment in the design process, management, clean energy and high-efficiency equipment and technology.
- In the medium term, by 2030, BDMS targets reducing greenhouse gas emissions by at least 30% from the base year of 2022. In 2023, the company cut greenhouse gas emissions 24.05% from the base year 2022.
- BDMS has set direction and sustainability goals in 2050 to increase the recycling of non-hazardous waste to 50% while promoting plastic container recycling and the use of biodegradable containers. In 2023, it utilized 24.46% of non-hazardous waste.

Governance Issue (G)

- BDMS Board of Directors has set up a corporate governance policy for executives, committee members and employees as operational guidelines.
- BDMS appointed a standardization and compliance committee to ensure all subsidiary hospitals operate in line with quality policies, patient safety plans and corporate strategy.
- In 2023, BDMS reviewed the Supplier Code of Conduct in the area of labor practices, non-discrimination and anti-harassment in the organization. In addition, it adheres to strict business integrity as well as ensuring green procurement and management to enable continued development throughout the supply chain. The company additionally does follow-up on supplier performance through an evaluation system to ensure compliance with the Supplier Code of Conduct.
- As of December 31, 2023, there were 15 directors in total, consisting of 7 executive directors (47% of all directors), 2 non-executive directors (13% of all directors) and 6 independent directors (40% of all directors). We view the structure as appropriate as independent directors are no fewer than one-third of the Board of Director members.
- The chairman is an independent director.
- Major shareholders control ~20% of total issued and paid-up shares.

Social Issue (S)

- In 2023, BDMS Medical Affairs Office set up BDMS Mandatory Courses. These courses encompass the group's Code of Conduct and good practices for physicians and dentists, including PDPA, informed consent, and other relevant laws to ensure physician awareness of insured patients as well as to communicate and foster an understanding of correct medical practices.
- BDMS set up a Quality Improvement and Patient Safety Plan Procedure to enhance the satisfaction and convenience of clients, employees and physicians, ensuring the wellbeing and trust of patients, including their family members. This handbook also includes assessment and adjustment of the corporate governance structure and management in line with JCI, HA standards and other related regulations. Performance must be reported at a minimum on a quarterly basis to the appropriate committee.
- We see ESG risk for healthcare service sector as patient safety and BDMS has adopted a variety of quality assurance systems to provide continuous patient care.

EGS Disclosure Score

	2023	2023
ESG Disclosure Score	58.92	60.12
Environment	54.27	56.00
Emissions Reduction Initiatives	No	No
Climate Change Policy	Yes	Yes
GHG Scope 1 ('000 metric tonnes)	8.67	33.69
GHG Scope 2 Location-Based ('000 metric tonnes)	95.94	208.85
Energy Efficiency Policy	Yes	Yes
Total Energy Consumption ('000 metric tonnes)	194.45	497.08
Waste Reduction Policy	Yes	Yes
Total Waste ('000 metric tonnes)	9.05	13.23
Water Policy	Yes	Yes
Total Water Withdrawal ('000 cubic meters)	249.84	435.79
Social	37.06	37.06
Human Rights Policy	Yes	Yes
Consumer Data Protection Policy	Yes	Yes
Pct Women in Workforce (%)	82.63	82.75
Lost Time Incident Rate - Employees (per 100 employees)	0.00	0.98
Number of Employees - CSR (persons)	36,880	40,495
Total Hours Spent by Firm - Employee Training (hours)	437,2091	,417,320

Governance	83.59	83.59
Size of the Board (persons)	18	17
Board Meeting Attendance Pct (%)	97	100
Number of Independent Directors (persons)	7	7
% Independent directors to total board members	39	41
Board Duration (Years)	3	3

Source: Bloomberg Finance L.P.

Disclaimer

Bloomberg ESG Disclosure Scores rate companies on their level of disclosure of ESG data. Bloomberg offers four disclosure scores, for overall ESG, as well as Environmental, Social, and Governance. To review the fully transparent methodology, calculate disclosure scores for any company, and compare a company's scores vs its peers, see ESG Disclosure Score Model in Bloomberg.



Financial statement

FY December 31	Unit	2019	2020	2021	2022	2023	2024F	2025F	2026F
Total revenue	(Btmn)	79,630	65,166	71,541	88,535	97,077	104,408	111,556	117,453
Cost of goods sold	(Btmn)	54,277	46,371	49,462	58,329	63,412	68,285	73,162	76,852
Gross profit	(Btmn)	25,354	18,795	22,079	30,205	33,665	36,123	38,394	40,600
SG&A	(Btmn)	17,447	14,161	15,029	17,655	19,806	20,417	21,271	22,147
Other income	(Btmn)	11,882	5,187	4,050	4,521	5,250	5,742	6,024	6,342
Interest expense	(Btmn)	929	871	728	632	547	503	423	303
Pre-tax profit	(Btmn)	18,860	8,950	10,373	16,440	18,563	20,946	22,724	24,493
Corporate tax	(Btmn)	3,873	2,751	2,103	3,227	3,755	4,231	4,590	4,948
Equity a/c profits	(Btmn)	1,022	273	21	42	89	94	99	103
Minority interests	(Btmn)	(492)	(435)	(554)	(648)	(522)	(627)	(752)	(902)
Core profit	(Btmn)	9,560	6,037	7,736	12,606	14,375	16,182	17,481	18,747
Extra-ordinary items	(Btmn)	5,957	1,177	200	0	0	0	0	0
Net Profit	(Btmn)	15,517	7,214	7,936	12,606	14,375	16,182	17,481	18,747
EBITDA	(Btmn)	18,032	14,982	17,622	23,021	24,957	27,381	29,402	31,197
Core EPS (Bt)	(Btmn)	0.61	0.38	0.49	0.79	0.90	1.02	1.10	1.18
Net EPS (Bt)	(Bt)	0.99	0.46	0.50	0.79	0.90	1.02	1.10	1.18
DPS (Bt)	(Bt)	0.55	0.55	0.45	0.60	0.70	0.79	0.85	0.91

Balance Sheet									
FY December 31	Unit	2019	2020	2021	2022	2023	2024F	2025F	2026F
Total current assets	(Btmn)	16,325	30,013	24,401	27,799	23,545	17,036	18,596	20,103
Total fixed assets	(Btmn)	78,440	81,313	79,689	81,860	87,025	90,226	93,675	97,351
Total assets	(Btmn)	133,662	136,050	128,454	141,543	143,596	139,884	144,490	149,269
Total loans	(Btmn)	24,316	20,701	15,672	15,998	10,499	4,000	4,000	4,000
Total current liabilities	(Btmn)	19,263	11,220	15,862	20,616	18,433	14,951	15,492	15,917
Total long-term liabilities	(Btmn)	24,099	20,594	15,596	15,498	9,499	4,000	4,000	4,000
Total liabilities	(Btmn)	46,480	44,588	40,689	47,830	44,723	37,243	37,784	38,208
Paid-up capital	(Btmn)	1,589	1,589	1,589	1,589	1,589	1,589	1,589	1,589
Total equity	(Btmn)	87,182	91,463	87,765	93,713	98,872	102,641	106,706	111,061
BVPS (Bt)	(Bt)	5.33	5.59	5.28	5.66	5.99	6.22	6.47	6.74

Cash Flow Statement

FY December 31	Unit	2019	2020	2021	2022	2023	2024F	2025F	2026F
Core Profit	(Btmn)	9,560	6,037	7,736	12,606	14,375	16,182	17,481	18,747
Depreciation and amortization	(Btmn)	5,752	6,413	6,321	5,950	5,848	5,932	6,255	6,400
Operating cash flow	(Btmn)	14,546	11,681	14,561	20,266	20,778	21,107	22,915	24,490
Investing cash flow	(Btmn)	2,818	12,385	(4,763)	(5,901)	(7,754)	(8,353)	(8,925)	(9,396)
Financing cash flow	(Btmn)	(17,701)	(9,096)	(18,531)	(12,631)	(17,897)	(19,420)	(13,415)	(14,392)
Net cash flow	(Btmn)	(337)	14,970	(8,733)	1,734	(4,873)	(6,665)	575	702

Key Financial Ratios

FY December 31	Unit	2019	2020	2021	2022	2023	2024F	2025F	2026F
Gross margin	(%)	31.8	28.8	30.9	34.1	34.7	34.6	34.4	34.6
Operating margin	(%)	9.9	7.1	9.9	14.2	14.3	15.0	15.3	15.7
EBITDA margin	(%)	21.5	21.7	23.3	24.7	24.4	24.9	25.0	25.2
EBIT margin	(%)	24.9	16.9	15.8	19.3	19.7	20.5	20.7	21.1
Net profit margin	(%)	19.5	11.1	11.1	14.2	14.8	15.5	15.7	16.0
ROE	(%)	11.9	6.8	8.6	13.9	14.9	16.1	16.7	17.2
ROA	(%)	7.2	4.5	5.8	9.3	10.1	11.4	12.3	12.8
Net D/E	(x)	0.3	(0.0)	0.1	0.1	0.0	0.0	0.0	(0.0)
Interest coverage	(x)	19.4	17.2	24.2	36.4	45.7	54.4	69.5	103.0
Debt service coverage	(x)	1.6	13.8	2.5	2.0	4.5	54.4	69.5	103.0
Payout Ratio	(%)	55.8	120.0	90.1	75.6	77.4	77.4	77.4	77.4

Main Assumptions

FY December 31	Unit	2019	2020	2021	2022	2023	2024F	2025F	2026F
Revenue by nationality									
International	(%)	30.0	21.0	18.0	24.0	27.4	28.6	29.9	30.4
Thai	(%)	70.0	79.0	82.0	76.0	72.6	71.4	70.1	69.6



Financial statement

FY December 31	Unit	3Q22	4Q22	1Q23	2Q23	3Q23	4Q23	1Q24	2Q24
Total revenue	(Btmn)	22,825	22,568	23,084	23,141	25,473	25,379	25,526	24,694
Cost of goods sold	(Btmn)	14,979	14,752	15,122	15,432	16,469	16,389	16,736	16,664
Gross profit	(Btmn)	7,846	7,816	7,962	7,709	9,003	8,990	8,790	8,030
SG&A	(Btmn)	4,496	4,933	4,633	4,876	5,106	5,191	4,893	5,146
Other income	(Btmn)	1,179	1,306	1,267	1,285	1,282	1,417	1,461	1,435
Interest expense	(Btmn)	154	169	164	134	122	126	113	111
Pre-tax profit	(Btmn)	4,374	4,020	4,432	3,983	5,057	5,091	5,246	4,208
Corporate tax	(Btmn)	824	806	882	812	1,025	1,035	1,042	756
Equity a/c profits	(Btmn)	16	10	34	13	21	22	13	14
Minority interests	(Btmn)	(181)	(111)	(117)	(120)	(163)	(123)	(143)	(131)
Core profit	(Btmn)	3,386	3,113	3,468	3,063	3,890	3,954	4,074	3,335
Extra-ordinary items	(Btmn)	0	0	0	0	0	0	0	0
Net Profit	(Btmn)	3,386	3,113	3,468	3,063	3,890	3,954	4,074	3,335
EBITDA	(Btmn)	6,018	5,673	6,025	5,563	6,649	6,720	6,835	5,822
Core EPS (Bt)	(Btmn)	0.21	0.20	0.22	0.19	0.24	0.25	0.26	0.21
Net EPS (Bt)	(Bt)	0.21	0.20	0.22	0.19	0.24	0.25	0.26	0.21

Balance Sheet

FY December 31	Unit	3Q22	4Q22	1Q23	2Q23	3Q23	4Q23	1Q24	2Q24
Total current assets	(Btmn)	27,074	27,799	30,419	23,705	23,295	23,545	26,663	23,545
Total fixed assets	(Btmn)	79,490	81,860	82,002	82,695	83,919	87,025	87,915	87,025
Total assets	(Btmn)	133,875	141,543	144,509	138,662	139,893	143,596	147,954	143,792
Total loans	(Btmn)	15,997	15,998	14,498	10,498	12,498	10,499	8,999	0
Total current liabilities	(Btmn)	22,966	20,616	21,941	18,477	20,732	18,433	18,008	18,433
Total long-term liabilities	(Btmn)	13,497	15,498	11,498	9,498	9,498	9,499	7,999	1,500
Total liabilities	(Btmn)	43,586	47,830	47,928	43,610	46,278	44,723	44,514	44,701
Paid-up capital	(Btmn)	1,589	1,589	1,589	1,589	1,589	1,589	1,589	1,589
Total equity	(Btmn)	90,289	93,713	96,581	95,051	93,614	98,872	103,441	99,091
BVPS (Bt)	(Bt)	5.41	5.66	5.88	5.78	5.67	5.99	6.27	6.01

Cash Flow Statement

FY December 31	Unit	3Q22	4Q22	1Q23	2Q23	3Q23	4Q23	1Q24	2Q24
Core Profit	(Btmn)	3,386	3,113	3,468	3,063	3,890	3,954	4,074	3,335
Depreciation and amortization	(Btmn)	1,490	1,484	1,429	1,446	1,470	1,503	1,477	1,503
Operating cash flow	(Btmn)	3,660	7,077	6,005	5,476	5,346	3,951	7,565	4,901
Investing cash flow	(Btmn)	(1,966)	(535)	(508)	(1,857)	(3,134)	(2,255)	(2,388)	(2,138)
Financing cash flow	(Btmn)	(4,980)	(4,468)	(1,679)	(9,662)	(4,440)	(2,116)	(1,700)	(6,955)
Net cash flow	(Btmn)	(3,285)	2,075	3,817	(6,043)	(2,227)	(421)	3,477	(4,193)

Key Financial Ratios

FY December 31	Unit	3Q22	4Q22	1Q23	2Q23	3Q23	4Q23	1Q24	2Q24
Gross margin	(%)	34.4	34.6	34.5	33.3	35.3	35.4	34.4	32.5
Operating margin	(%)	14.7	12.8	14.4	12.2	15.3	15.0	15.3	11.7
EBITDA margin	(%)	25.1	23.8	24.7	22.8	24.9	25.1	25.3	22.3
EBIT margin	(%)	19.8	18.6	19.9	17.8	20.3	20.6	21.0	17.5
Net profit margin	(%)	14.8	13.8	15.0	13.2	15.3	15.6	16.0	13.5
ROE	(%)	14.5	13.9	14.8	14.0	15.1	14.9	16.3	15.3
ROA	(%)	9.6	9.3	10.1	9.6	10.2	10.1	11.1	10.5
Net D/E	(x)	0.1	0.1	(0.0)	0.0	0.0	0.0	(0.0)	(0.0)
Interest coverage	(x)	39.1	33.6	36.7	41.5	54.4	53.2	60.7	52.7
Debt service coverage	(x)	3.0	3.7	3.9	7.3	5.3	8.9	18.9	52.7

Main Assumptions									
FY December 31	Unit	3Q22	4Q22	1Q23	2Q23	3Q23	4Q23	1Q24	2Q24
Revenue by nationality									
International	(%)	24.0	27.0	29.5	26.0	26.0	28.0	30.0	27.0
Thai	(%)	76.0	73.0	70.5	74.0	74.0	72.0	70.0	73.0




Figure 1: BDMS 2Q24 earnings review

Bt mn)	2Q23	3Q23	4Q23	1Q24	2Q24	ΥοΥ%	QoQ%	1H23	1H24	ΥοΥ%
Revenue	23,141	25,473	25,379	25,526	24,694	6.7	(3.3)	46,225	50,219	8.6
Gross profit	7,709	9,003	8,990	8,790	8,030	4.2	(8.6)	15,671	16,820	7.3
EBITDA	5,563	6,649	6,720	6,835	5,822	4.6	(14.8)	11,588	12,656	9.2
Core profit	3,063	3,890	3,954	4,074	3,335	8.9	(18.1)	6,531	7,408	13.4
Net profit	3,063	3,890	3,954	4,074	3,335	8.9	(18.1)	6,531	7,408	13.4
EPS (Bt/share)	0.19	0.24	0.25	0.26	0.21	8.9	(18.1)	0.41	0.47	13.4
Balance Sheet										
Fotal Assets	138,662	139,893	143,596	147,954	143,792	3.7	(2.8)	138,662	143,792	3.7
Fotal Liabilities	43,610	46,278	44,723	44,514	44,701	2.5	0.4	43,610	44,701	2.5
Fotal Equity	95,051	93,614	98,872	103,441	99,091	4.3	(4.2)	95,051	99,091	4.3
3VPS (Bt/share)	5.78	5.67	5.99	6.27	6.01	4.0	(4.3)	5.78	6.01	4.0
Financial Ratio										
Gross Margin (%)	33.3	35.3	35.4	34.4	32.5	(0.8)	(1.9)	33.9	33.5	(0.4)
EBITDA margin (%)	22.8	24.9	25.1	25.3	22.3	(0.5)	(3.0)	23.8	23.8	0.1
Net Profit Margin (%)	13.2	15.3	15.6	16.0	13.5	0.3	(2.5)	14.1	14.8	0.6
ROA (%)	9.0	11.4	11.1	11.1	9.4			9.0	9.4	
ROE (%)	13.2	16.9	16.4	16.3	13.7			13.2	13.7	
nterest-bearing-debt to equity (x)	0.21	0.23	0.20	0.09	0.08			0.21	0.08	
Bt mn)	2Q23	3Q23	4Q23	1Q24	2Q24	% YoY	% QoQ	1H23	1H24	ΥοΥ%
<u>Revenue by nationality</u>										
Гһаі	17,124	18,850	18,273	17,868	18,026	5.3	0.9	33,398	35,894	7.5
nternational patients	6,017	6,623	7,106	7,658	6,667	10.8	(12.9)	12,826	14,325	11.7
Fotal revenue	23,141	25,473	25,379	25,526	24,694	6.7	(3.3)	46,225	50,219	8.6
							(3.3)			


Source: InnovestX Research

Figure 2: Earnings forecast



Source: InnovestX Research

Figure 3: BDMS valuation is undemanding



Source: SET and InnovestX Research

PE band since 2015, excluding 2020-21 which is an exceptional COVID-19 period

Figure 4: Valuation summary (price as of Aug 13, 2024)

-																					
	Rating	Price	Target	ETR	Ρ,	/E (x)	EPS growth (%)		P/BV (x)		ROE (%)		6)	Div. Yield (%)			EV/EBITDA (x)		(x)		
		(Bt/Sh)	(Bt/Sh)	(%)	23A	24F 25F	23A	24F 2	5F	23A	24F	25F	23A 2	24F	25F	23A	24F	25F	23A	24F	25F
BCH	Outperform	15.80	23.0	48.1	26.4	24.5 20.7	(63.0)	7.7 18	3.3	3.1	3.0	2.8	11	11	13	2.2	2.5	3.0	13.3	12.2	10.6
BDMS	Outperform	27.75	36.0	32.6	30.7	27.3 25.2	14.0	12.6 8	3.0	4.6	4.5	4.3	15	16	17	2.5	2.8	3.1	18.1	16.4	15.3
BH	Neutral	245.00	270.0	12.2	28.1	25.1 23.9	40.0	12.2	5.1	8.2	7.0	6.1	31	30	27	1.8	2.0	2.1	22.2	16.8	15.5
CHG	Neutral	2.42	3.5	47.8	24.4	21.8 18.6	(60.7)	11.6 17	7.6	3.5	3.4	3.1	14	15	17	2.9	3.2	3.8	14.1	12.2	10.7
RJH	Neutral	22.50	28.0	29.9	16.1	15.7 15.2	(59.3)	2.4 3	3.4	3.3	3.2	3.1	18	18	18	5.3	5.4	5.6	11.0	10.6	10.1
Average					25.1	22.9 20.7	(25.8)	9.3 10).5	4.9	4.4	4.1	18	18	18	2.4	2.7	3.0	16.9	14.4	13.0

Source: InnovestX Research



Disclaimer

The information in this report has been obtained from sources believed to be reliable. However, its accuracy or completeness is not guaranteed. Any opinions expressed herein reflect our judgment at this date and are subject to change without notice. This report is for information only. It is not to be construed as an offer, or solicitation of an offer to sell or buy any securities. We accept no liability for any loss arising from the use of this document. We or our associates may have an interest in the companies mentioned therein.

InnovestX Securities Company Limited ("INVX") is wholly owned by SCB X Public Company Limited ("SCBX") and The Siam Commercial Bank Public Company Limited ("SCB") is majority-owned by SCBX. Any information related to SCB is for sector comparison purpose.

This document is prepared by InnovestX Securities Company Limited ("INVX") which is wholly owned by SCB X Public Company Limited ("SCBX"). The Siam Commercial Bank Public Company Limited, which is majority-owned by SCBX, acts as financial advisor of the LH Hotel Leasehold Real Estate Investment Trust. Any opinions, news, research, analyses, prices, statements, forecasts, projections and/or other information contained in this document (the "Information") is provided as general information purposes only and shall not be construed as individualized recommendation of an offer to buy or sell or the solicitation of an offer to buy or sell any securities. INVX and/or its directors, officers and employees shall not be liable for any direct, indirect, incidental, special or consequential loss or damage, resulting from the use of or reliance on the Information, including without limitation to, damages for loss of profits. The investors shall use the Information in association with other information and opinion, including their own judgment in making investment decision. The Information is obtained from sources believed to be reliable, and INVX cannot guarantee the accuracy, completeness and/or correctness of the Information.

INVX reserves the right to modify the Information from time to time without notice and in its sole discretion. This document is delivered to intended recipient(s) only and is not permitted to reproduce, retransmit, disseminate, sell, distribute, republish, circulate or commercially exploit the Information in any manner without the prior written consent of INVX.

Futures and Options trading carry a high level of risk with the potential for substantial losses, and are not suitable for all persons. Before deciding to trade Futures and Options, you should carefully consider your financial position, investment objectives, level of experience, and risk appetite if Futures and Options trading are appropriate. The possibility exists that you could sustain a loss of some or all of your initial investment. You should be aware of all the risks associated with Futures and Options trading, and you are advised to rely on your own judgment while making investment decision and/or should seek advice from professional investment advisor if you have any doubts.

This document is delivered to intended recipient(s) only and is not permitted to reproduce, retransmit, disseminate, sell, distribute, republish, circulate or commercially exploit the Information in any manner without the prior written consent of INVX.

© Copyright 2022 InnovestX Securities Co., Ltd. All right reserved.



CG Rating 2023 Companies with CG Rating

Companies with Excellent CG Scoring

7UP, AAV, ABM, ACE, ACG, ADB, ADD, ADVANC, AEONTS, AF, AGE, AH, AHC, AIRA, AIT, AJ, AKP, AKR, ALLA, ALT, AMA, AMARIN, AMATA, AMATAV, ANAN, AOT, AP, APCO, APCS, ARIP, ARROW, ASEFA, ASK, ASP, ASW, ATP30, AUCT, AWC, AYUD, B, BA, BAFS, BAM, BANPU, BAY, BBGI, BBIK, BBL, BC, BCH, BCP, BCPG, BDMS, BEC, BEM, BEYOND, BGC, BGRIM, BH, BIZ, BJC, BJCHI, BKI, BLA, BOL, BPP, BRI, BROOK, BRR, BTS, BTW, BWG, BYD, CBG, CENTEL, CFRESH, CHASE, CHEWA, CHG, CHOW, CIMBT, CIVIL, CK, CKP, CM, CNT, COLOR, COM7, COTTO, CPALL, CPAXT, CPF, CPI, CPL, CPN, CPW, CRC, CRD, CSC, CSS, CV, DCC, DDD, DELTA, DEMCO, DMT, DOHOME, DRT, DUSIT, EA, EASTW, ECF, ECL, EE, EGCO, EPG, ICC, ICTL, ICN, III, ILINK, ILM, IMH, IND, INET, INTUCH, IP, IRC, IRPC, ITC, ITEL, IVL, JAS, JTS, KBANK, KCC, KCE, KEX, KKP, KSL, KTB, KTC, KTMS, KUMWEL, KUN, LALIN, LANNA, LH, LHFG, LIT, LOXLEY, LPN, LRH, LST, M, MAJOR, MALEE, MATCH, MBK, MC, M-CHAI, MCOT, MEGA, MFC, MFEC, MILL, MINT, MONO, MOONG, MSC, MST, MTC, MTI, NC, NCH, NCL, NDR, NER, NKI, NOBLE, NRF, NTV, NVD, NWR, NYT, OCC, OISHI', ONEE, OR, ORI, OSP, OTO, PAP, PATO, PB, PCSGH, PDG, PDJ, PG, PHOL, PIMO, PJW, PLANB, PLAT, PLUS, PM, POLY, PORT, PPP, PPS, RP9, PRG, PRINC, PRM, PRTR, PSH, PSL, PT, PTC, PTT, PTTEP, PTTEC, Q-CON, QH, QTC, RATCH, RBF, RPH, RS, RT, S, S&J, SA, SABINA, SAK, SAMART, SAMTEL, SAPPE, SAT, SBNEXT, SC, SCB, SCC, SCCG, SCGP, SCM, SDC, SEAFCO, SEAOIL, SECURE, SELIC, SENA, SENX, SFP², SFT, SGC, SGF, SGP, SHR, SICT, SIRI, SIS, SINHAI, SJMD, SYNTEC, TACC, TAE, TCAP, TCMC, TEAMMA, TEG, TGH, TFG, TFMAMAA, TGE, TGH, THANA, THANN, THAOM, THHP, THRE, THREL, TIDLOR, TIPH, TISCO, TK, TNT, TUN, TVA, TVM, TVO, TVT, TWPC, UAC, UBE, UBIS, UKEM, UP, UPF, UPOIC, UV, VCOM, VGI, VIBHA, VIH, VL, WACOAL, WGE, WHA, WHAUP, WICE, WINMED, WINNER, XPG, YUASA, ZEN

Companies with Very Good CG Scoring

25, A5, AAI, AIE, ALUCON, AMR, APURE, ARIN, AS, ASIA, ASIAN, ASIMAR, ASN, AURA, BR, BSBM, BSRC, BTG, CEN, CGH, CH, CHIC, CI, CIG, CMC, COMAN, CSP, DOD, DPAINT, DV8, EFORL, EKH, ESTAR, EVER, FORTH, FSMART, FTI, GEL, GPI, HEALTH, HUMAN, IFS, INSET, IT, J, JCKH, JDF, JKN, JMART, JUBILE, K, KCAR, KGI, KIAT, KISS, KK, KTIS, KWC, KWM, LDC, LEO, LHK, MACO, METCO, MICRO, MK, MVP, NCAP, NOVA, NTSC, PACO, PIN, PQS, PREB, PRI, PRIME, PROEN, PROS, PROUD, PSTC, PTECH, PYLON, RCL, SALEE, SANKO, SCI, SCN, SE, SE-ED, SFLEX, SINGER, SKN, SONIC, SORKON, SPVI, SSP, SST, STANLY, STP, SUPER, SVOA, SWC, TCC, TEKA, TFM, TMILL, TNP, TPLAS, TPOLY, TRC, TRU, TRUBB, TSE, VRANDA, WAVE. WFX. WIIK, WIN, WP, XO

Companies with Good CG Scoring

24CS, AMANAH, AMARC, AMC, APP, ASAP, BCT, BE8, BIG, BIOTEC, BLESS, BSM, BVG, CAZ, CCET, CHARAN, CHAYO, CHOTI, CITY, CMAN, CMR, CRANE, CWT, DHOUSE, DTCENT, EASON, FNS, FTE, GIFT, GJS, GTB, GTV, GYT, HL, HTECH, HYDRO, IIG, INGRS, INSURE, IRCP, ITD, ITNS, JCK, JMT, JR, JSP, KBS, KGEN, KJL, L&E, LEE, MASTER, MBAX, MEB, MENA, META, MGT, MITSIB, MJD, MOSHI, MUD, NATION, NNCL, NPK, NSL, NV, OGC, PAF, PCC, PEACE, PICO, PK, PL, PLANET, PLE, PMTA, PPM, PRAKIT, PRAPAT, PRECHA, PRIN, PSG, RABBIT, READY, RJH, RSP, RWI, S11, SAAM, SAF, SAMCO, SAWAD, SCAP, SCP, SIAM, SKE, SKY, SMART, SMD, SMIT, SOLAR, SPA, STECH, STPI, SVR, TC, TCCC³, TEAM, TFI, TIGER, TITLE, TKC, TMI, TNH, TPA, TPAC, TRITN, UBA, UMI, UMS, UTP, VARO, VPO, W, WARRIX, WORK, WPH, YONG, ZIGA

Corporate Governance Report

The material contained in this publication is for general information only and is not intended as advice on any of the matters discussed herein. Readers and others should perform their own independent analysis as to the accuracy or completeness or legality of such information. The Thai Institute of Directors, its officers, the authors and editor make no representation or warranty as to the accuracy, completeness or legality of any of the information contained herein. By accepting this document, each recipient agrees that the Thai Institute of Directors Association, its officers, the authors and editor shall not have any liability for any information contained in, or for any omission from, this publication. The survey result is as of the date appearing in the Corporate Governance Report of Thai Listed Companies. As a result, the survey result may be changed after that date. InnovestX Securities Company Limited does not conform nor certify the accuracy of such survey result.

To recognize well performers, the list of companies attaining "Good", "Very Good" and "Excellent" levels of recognition (Not including listed companies qualified in the "no

announcement of the results" clause from 1 January 2022 to 31 October 2023) is publicized.

¹OISHI was voluntarily delisted from the Stock Exchange of Thailand, effectively on September 6, 2023 ²SFP was voluntarily delisted from the Stock Exchange of Thailand, effectively on July 19, 2023

The way voluntarily defisited from the stock excitating of maintain, effectively of July 19, 2023

³TCCC was voluntarily delisted from the Stock Exchange of Thailand effectively on August 25, 2023

Anti-corruption Progress Indicator

Certified (ໄດ້ຮັບກາຣຮັບຣອง)

2S, AAI, ADVANC, AE, AF, AH, AI, AIE, AIRA, AJ, AKP, AMA, AMANAH, AMATA, AMATAV, AP, APCS, AS, ASIAN, ASK, ASP, AWC, AYUD, B, BAFS, BAM, BANPU, BAY, BBGI, BBL, BCH, BCP, BCPG, BE8, BEC, BEYOND, BGC, BGRIM, BLA, BPP, BRR, BSBM, BTC, BTS, BWG, CCN, CENTEL, CFRESH, CGH, CHEWA, CHOTI, CHOW, CIG, CIMBT, CM, CMC, COM7, CPALL, CPAXT, CPF, CPI, CPL, CPN, CPW, CRC, CSC, DCC, DELTA, DEMCO, DIMET, DOHOME, DRT, DUSIT, EA, EASTW, ECF, EGCO, EP, EPG, ERW, ESTAR, ETC, ETE, FNS, FPI, FSMART, FTE, GBX, GC, GCAP, GEL, GFPT, GGC, GJS, GPI, GPSC, GSTEEL, GULF, GUNKUL, HANA, HARN, HENG, HMPRO, HTC, ICC, ICHI, IFS, III, ILINK, ILM, INET, INOX, INSURE, INTUCH, IRPC, ITEL, IVL, JAS, JKN, JR, JTS, KASET, KBANK, KBS, KCAR, KCE, KGEN, KGI, KKP, KSL, KTB, KTC, L&E, LANNA, LHFG, LHK, LPN, LRH, M, MAJOR, MALEE, MATCH, MBX, MBK, MC, MCOT, META, MFC, MFEC, MILL, MINT, MONO, MOONG, MSC, MST, MTC, MTI, NATION, NCAP, NEP, NKI, NOBLE, NRF, NWR, OCC, OGC, OR, ORI, PAP, PATO, PB, PCSCH, PDG, PDJ, PG, PHOL, PIMO, PK, PL, PLANB, PLANET, PLAT, PM, PPP, PPPM, PPS, PR9, PREB, PRG, PRINC, PRM, PROS, PSH, PSL, PSTC, PT, PTECH, PTG, PTT, PTTEP, PTTGC, PYLON, Q-CON, QH, QLT, QTC, RABBIT, RATCH, RML, RS, RWI, S&J, SAAM, SABINA, SAK, SAPPE, SAT, SC, SCC, SCC, SCG, SCGP, SCM, SCN, SEAOIL, SE-ED, SELIC, SENA, SGC, SGP, SIRI, SITHAI, SKR, SMIT, SMK, SMPC, SNC, SNP, SORKON, SPACK, SPALL, SPC, SPI, SPRC, SRICHA, SSF, SSP, SSSC, SST, STA, STGT, STOWER, SUSCO, SVI, SYNC, SYNTEC, TAE, TAKUNI, TASCO, TCAP, TCMC, TFG, TFI, TFMAMA, TGE, TGH, THANI, THCOM, THIP, THRE, THREL, TIDLOR, TIPCO, TISCO, TKS, TKT, TMD, TMILL, TMT, TNITY, TNL, TNP, TNR, TOG, TOP, TOPP, TPA, TPCS, TRT, TRU, TSC, TSI, TSTE, TSTH, TTA, TTB, TTCL, TU, TVDH, TVO, TWPC, UBE, UBIS, UEC, UKEM, UOBKH, UV, VCOM, VGI, VIH, WACOAL, WHA, WHAUP, WICE, WIIK, XO, YUASA, ZEN, ZIGA

Declared (ประกาศเจตนารมณ์)

ACE, ADB, ALT, AMC, ASW, BLAND, BTG, BYD, CAZ, CBG, CV, DEXON, DMT, EKH, FSX, GLOBAL, GREEN, ICN, IHL, ITC, J, JMART, JMT, LEO, LH, MENA, MITSIB, MODERN, NER, NEX, OSP, PEER, PLUS, POLY, PQS, PRIME, PROEN, PRTR, RBF, RT, SA, SANKO, SCB, SENX, SFLEX, SIS, SKE, SM, SVOA, TBN, TEGH, TIPH, TKN, TPAC, TPLAS, TQM, TRUE, W, WPH, XPG N/A

24CS, 3K-BAT, A, A5, AAV, ABM, ACAP, ACC, ACG, ADD, ADVICE, AEONTS, AFC, AGE, AHC, AIT, AJA, AKR, AKS, ALL, ALLA, ALPHAX, ALUCON, AMARC, AMARIN, AMR, ANAN, ANI, AOT, APCO, APEX, APO, APP, APURE, AQUA, ARIN, ARIP, ARROW, ASAP, ASEFA, ASIA, ASIMAR, ASN, ATP30, AU, AUCT, AURA, B52, BA, BBIK, BC, BCT, BDMS, BEAUTY, BEM, BGT, BH, BIG, BIOTEC, BIS, BIZ, BJC, BJCHI, BKD, BKGI, BKIH, BLC, BLESS, BLISS, BM, BOL, BPS, BR, BRI, BROCK, BSM, BSRC, BTNC, BTW, BUI, BVG, CCET, CCP, CEYE, CFARM, CGD, CH, CHAO, CHARAN, CHASE, CHAYO, CHG, CHIC, CHO, CL CITY, CIVIL, CK, CKP, CMAN, CMO, CMR, CNT, COCOCO, COLOR, COMAN, CPANEL, CPL, CPR, CPT, CRANE, CRD, CREDIT, CSP, CSR, CSS, CTW, CWT, D, DCON, DDD, DHOUSE, DITTO, DOD, DPAINT, DTCENT, DTCI, DV8, EASON, ECL, EE, EFORL, EMC, ETL, EURO, EVER, F&D, FANCY, FE, FLOYD, FM, FMT, FN, FORTH, FTI, FVC, GABLE, GENCO, GFC, GIFT, GL, GLAND, GLOCON, GLORY, GRAMMY, GRAND, GSC, GTB, GTV, GYT, HEALTH, HFT, HL, HPT, HTECH, HUMAN, HYDRO, 12, IIG, IMH, IND, INGRS, INSET, IP, IRC, IRCP, IT, ITD, ITNS, ITTHI, JAK, JCK, JCKH, JCT, JDF, JPARK, JSP, JUBILE, K, KAMART, KC, KCC, KCG, KCM, KDH, KEX, KIAT, KISS, KJL, KK, KKC, KLINIQ, KOOL, KTIS, KTMS, KUMWEL, KUN, KWC, KWI, KWM, KYE, LALIN, LDC, LEE, LIT, LOXLEY, LPH, LST, LTS, MAGURO, MANRIN, MASTER, MATI, MCA, M-CHAI, MCS, MDX, MEB, MEGA, METCO, MGC, MGI, MGT, MICRO, MIDA, MJD, MK, ML, MORE, MOSHI, MTW, MUD, MVP, NAM, NAT, NC, NCH, NCL, NCP, NDR, NEO, NETBAY, NEW, NEWS, NFC, NL, NNCL, NOK, NOVA, NPK, NSL, NTSC, NTV, NUSA, NV, NVD, NYT, OHTL, ONEE, ORN, PACO, PAF, PANEL, PCC, PEACE, PERM, PF, PHG, PICO, PIN, PJW, PLE, PLT, PMTA, POLAR, PORT, PPM, PRAKIT, PRAPAT, PRECHA, PRI, PRIN, PRO, PROUD, PSG, PSP, PTC, PTL, QTCG, RAM, RCL, READY, RICHY, RJH, ROCK, ROCTEC, ROH, ROJNA, RP, RPC, RPH, RSP, S, S11, SABUY, SAF, SAFARI, SAFE, SALEE, SAM, SAMART, SAMCO, SAMTEL, SAUCE, SAV, SAWAD, SAWANG, SBNEXT, SCAP, SCGD, SCI, SCL, SCP, SDC, SE, SEAFCO, SECURE, SFT, SGF, SHANG, SHR, SIAM, SICT, SIMAT, SINGER, SINO, SISB, SJWD, SK, SKN, SKY, SLM, SLP, SMART, SMD, SMT, SNNP, SO, SOLAR, SONIC, SPA, SPCG, SPG, SPREME, SPVI, SQ, SR, SSC, STANLY, STARK, STC, STEC, STECH, STHAI, STI, STP, STX, SUC, SUN, SUPER, SUTHA, SVR, SVT, SWC, SYNEX, TACC, TAN, TAPAC, TC, TCC, TCJ, TCOAT, TEAM, TEAMG, TEKA, TERA, TFM, TGPRO, TH, THAI, THANA, THE, THG, THMUI, TIGER, TITLE, TK, TKC, TLI, TM, TMC, TMI, TMW, TNDT, TNH, TNPC, TOA, TPBI, TPCH, TPIPL, TPIPL, TPOLY, TPP, TPS, TQR, TR, TRC, TRITN, TRP, TRUBB, TRV, TSE, TTI, TTT, TTW, TURTLE, TVH, TVT, TWP, TWZ, TYCN, UAC, UBA, UMI, UMS, UNIQ, UP, UPF, UPOIC, UREKA, UTP, UVAN, VARO, VIBHA, VL, VNG, VPO, VRANDA, WARRIX, WAVE, WELL, WFX, WGE, WIN, WINDOW, WINMED, WINNER, WORK, WORLD, WP, YGG, YONG, ZAA

Explanations

Companies participating in Thailand's Private Sector Collective Action Coalition Against Corruption programme (Thai CAC) under Thai Institute of Directors (as of November 1, 2023) are categorised into: companies that have declared their intention to join CAC, and companies certified by CAC.